Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $657.6 million.

  • Apellis Pharmaceuticals' Total Liabilities fell 108.16% to $657.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $657.6 million, marking a year-over-year decrease of 108.16%. This contributed to the annual value of $656.5 million for FY2024, which is 1048.5% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Total Liabilities stood at $657.6 million, which was down 108.16% from $665.1 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Total Liabilities' 5-year high stood at $841.4 million during Q2 2021, with a 5-year trough of $565.3 million in Q1 2024.
  • In the last 5 years, Apellis Pharmaceuticals' Total Liabilities had a median value of $643.1 million in 2025 and averaged $641.2 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 7641.24% in 2021, then tumbled by 2059.95% in 2022.
  • Apellis Pharmaceuticals' Total Liabilities (Quarter) stood at $683.1 million in 2021, then dropped by 13.58% to $590.3 million in 2022, then increased by 0.65% to $594.2 million in 2023, then grew by 10.49% to $656.5 million in 2024, then rose by 0.16% to $657.6 million in 2025.
  • Its Total Liabilities stands at $657.6 million for Q3 2025, versus $665.1 million for Q2 2025 and $643.1 million for Q1 2025.